Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal web...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2021-09-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/cipms-2021-0024 |
| _version_ | 1818983169987182592 |
|---|---|
| author | Gillani Syed Wasif Azhar Anam Gulam Shabaz Mohiuddin Gebreigziabher Fithawit Bahran Rathore Hassaan Anwer |
| author_facet | Gillani Syed Wasif Azhar Anam Gulam Shabaz Mohiuddin Gebreigziabher Fithawit Bahran Rathore Hassaan Anwer |
| author_sort | Gillani Syed Wasif |
| collection | DOAJ |
| description | The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal websites like SCOPUS, Science direct, Cochrane review library etc. were used. The articles were evaluated based on the search and eligibility criteria. A total of five RCTs were incorporated in this meta-analysis. These studies contained a total of 1058 patients, including 526 patients with placebo (or control-treated patients), and 532 patients with empagliflozin (25 mg) treated combination. The mean follow-up time ranged from 7 days to 6 months. Overall, mean reduction in placebo was -0.50% and empa-treated was -0.85%, while the pooled WMD was 3.82 995% CI 1.20 – 5.88, p=0.0001). Regarding urinary glucose excretion, that the pooled WMD was 6.67 (95% CI 4.87-10.14, p=0.001) indicated a significant increase in empa-arm compared to placebo. No heterogeneity was found (I2 – 15.03%). This meta-analysis underlined the therapeutic benefit of empagliflozin as an adjunctive therapy for patients with type 1 diabetes. |
| first_indexed | 2024-12-20T17:58:51Z |
| format | Article |
| id | doaj.art-3c3b254bd1ef487aaed0f63d553cfbe4 |
| institution | Directory Open Access Journal |
| issn | 2300-6676 |
| language | English |
| last_indexed | 2024-12-20T17:58:51Z |
| publishDate | 2021-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Current Issues in Pharmacy and Medical Sciences |
| spelling | doaj.art-3c3b254bd1ef487aaed0f63d553cfbe42022-12-21T19:30:41ZengSciendoCurrent Issues in Pharmacy and Medical Sciences2300-66762021-09-0134312312910.2478/cipms-2021-0024Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trialsGillani Syed Wasif0Azhar Anam1Gulam Shabaz Mohiuddin2Gebreigziabher Fithawit Bahran3Rathore Hassaan Anwer4Department of Pharmacy Practice, College of Pharmacy Gulf Medical University, Ajman, United Arab EmiratesPharm D candidates, College of Pharmacy Gulf Medical University, Ajman, United Arab EmiratesDepartment of Pharmacy Practice, College of Pharmacy Gulf Medical University, Ajman, United Arab EmiratesDepartment of Pharmacy Practice, College of Pharmacy Gulf Medical University, Ajman, United Arab EmiratesCollege of Pharmacy, Qatar University, Doha, QatarThe objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal websites like SCOPUS, Science direct, Cochrane review library etc. were used. The articles were evaluated based on the search and eligibility criteria. A total of five RCTs were incorporated in this meta-analysis. These studies contained a total of 1058 patients, including 526 patients with placebo (or control-treated patients), and 532 patients with empagliflozin (25 mg) treated combination. The mean follow-up time ranged from 7 days to 6 months. Overall, mean reduction in placebo was -0.50% and empa-treated was -0.85%, while the pooled WMD was 3.82 995% CI 1.20 – 5.88, p=0.0001). Regarding urinary glucose excretion, that the pooled WMD was 6.67 (95% CI 4.87-10.14, p=0.001) indicated a significant increase in empa-arm compared to placebo. No heterogeneity was found (I2 – 15.03%). This meta-analysis underlined the therapeutic benefit of empagliflozin as an adjunctive therapy for patients with type 1 diabetes.https://doi.org/10.2478/cipms-2021-0024meta-analysistype 1 diabetesempagliflozinplaceboevidence-based practice |
| spellingShingle | Gillani Syed Wasif Azhar Anam Gulam Shabaz Mohiuddin Gebreigziabher Fithawit Bahran Rathore Hassaan Anwer Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials Current Issues in Pharmacy and Medical Sciences meta-analysis type 1 diabetes empagliflozin placebo evidence-based practice |
| title | Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials |
| title_full | Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials |
| title_fullStr | Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials |
| title_full_unstemmed | Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials |
| title_short | Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials |
| title_sort | comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus a meta analysis of randomized controlled trials |
| topic | meta-analysis type 1 diabetes empagliflozin placebo evidence-based practice |
| url | https://doi.org/10.2478/cipms-2021-0024 |
| work_keys_str_mv | AT gillanisyedwasif comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT azharanam comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT gulamshabazmohiuddin comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT gebreigziabherfithawitbahran comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT rathorehassaananwer comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials |